Verve Therapeutics - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeVerve Therapeutics
Verve Therapeutics logo

Verve Therapeutics

0 followers

VERV

Performance

About Verve Therapeutics

Verve Therapeutics is a biotechnology company focused on developing genetic medicines to prevent cardiovascular disease. The company emphasizes gene editing approaches, delivery systems, and genetic targets to treat cardiovascular conditions, aiming to address the global burden of ASCVD. Its pipeline includes programs such as VERVE-102 and VERVE-201, reflecting a focus on in vivo genetic interventions for cardiovascular disease. Verve Therapeutics operates in the field of cardiovascular biotech, pursuing therapies that could reduce disease risk and improve outcomes worldwide.

Recent News

Recent Deals

No recent deals for this company.

Key Team Members

Sekar Kathiresan, M.D.

Co-Founder, Chief Executive Officer

Key Facts

HQ Location

Boston, United States

Founded

2018

Employees

201 - 500

Status

Public

Website

https://vervetx.com